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Abstract word count: 300 
Citable statement: An economic analysis shows that replacing high dead space syringes with 
detachable low dead space syringes at needle and syringe programmes is a cost-saving approach to 
reducing hepatitis C transmission among people who inject drugs. 
Abstract 
Background and Aims:  
Traditional detachable syringes used by people who inject drugs (PWID) retain larger volumes of blood 
when the plunger is depressed than syringes with fixed needles - referred to as high (HDSS) and low 
dead space syringes (LDSS), respectively. Evidence suggests that using HDSS may result in greater 
hepatitis C virus (HCV) transmission risk than LDSS. We evaluated the cost-effectiveness of an 
intervention to introduce detachable LDSS in a needle and syringe programme (NSP). 
Design: HCV transmission and disease progression model with cost-effectiveness analysis using a 
health-care perspective. Detachable LDSS are associated with increased costs (£0.01) per syringe, 
yearly staff training costs (£536) and an estimated decreased risk (by 47.5%) of HCV transmission 
compared to HDSS. The intervention was modelled for 10 years, with costs and health benefits 
(quality-adjusted life-years or QALYs) tracked over 50 years.  
Setting: Bristol, UK 
Participants/Cases: PWID attending NSP 
Intervention and comparator: Gradual replacement of HDSS at NSP, with 8%, 58% and 95% of HDSS 
being replaced by detachable LDSS in 2016, 2017 and 2018, respectively. Comparator was continuing 
use of HDSS. 
Measurements: Net monetary benefit. Benefits were measured in QALYs. 
Findings: Introducing detachable LDSS was associated with a small increase in intervention costs 
(£21,717) compared to not introducing detachable LDSS, but considerable savings in HCV-related 
treatment and care costs (£4,138,118). Overall cost savings were £4,116,401 over 50 years and QALY 
gains were 1,000, with an estimated 30% reduction in new infections over the 10 year intervention 
period. In all sensitivity analyses, detachable LDSS resulted in cost savings and additional QALYs. 
Threshold analyses suggested detachable LDSS would need to reduce HCV transmission risk of HDSS 
by 0.26% to be cost-saving and 0.04% to be cost-effective. 
Conclusions: Replacing HDSS with detachable LDSS in NSPs is likely to be a cost-saving approach for 






Hepatitis C virus (HCV) is a blood borne virus (BBV) with considerable burden globally, with over half 
of the estimated 15 million people who inject drugs (PWID) being infected(1). In the United Kingdom 
(UK), there are approximately 200,000 individuals that have been infected with HCV, of whom over 
80% are PWID or have an injecting history(2,3). Hospital admissions due to end-stage liver disease and 
hepatocellular carcinoma (HCC) nearly tripled between 2004 and 2013, while deaths from HCV more 
than doubled(4).  
The primary interventions for preventing HCV transmission are needle and syringe programmes (NSP) 
and opioid substitution therapy (OST), which have high coverage (>50%) in the UK(5). Although 
evidence suggests these interventions are effective at reducing the risk of HCV acquisition(6), HCV 
transmission rates among PWID remain high in the UK(4) and globally(1).  
PWID either use syringes with fixed or detachable needles. Syringes with fixed needles are traditionally 
termed low dead space syringes (LDSS) because their design minimises the amount of dead space 
between the syringe hub and needle (volume of space in which fluid is retained) when the plunger is 
fully depressed(7,8). In contrast, traditional syringes with detachable needles have greater dead 
space, and are termed high dead space syringes (HDSS) (Figure 1). Existing evidence suggests that if 
LDSS are re-used they will be less infectious than HDSS because they retain less blood(9). Laboratory 
studies have shown that LDSS retain less viable HCV in the syringe in subsequent injections than 
HDSS(8,10), while modelling(11,12) has shown that smaller quantities of blood are transferred with 
LDSS than HDSS. Limited epidemiological studies also suggest lower HIV and HCV prevalence rates  
among PWID that use LDSS(13–16), although these studies have not measured incident infection and 
only one UK study adequately controlled for other factors that could affect infection risk(13). 
The World Health Organisation (WHO)(17) and National Institute for Health and Care Excellence 
(NICE)(18) recommend that NSPs provide and encourage the use of LDSS by PWID. However, most 
LDSS are only available in small sizes (≤1 ml) with short needles(7), and so PWID requiring or preferring 
larger syringes and/or detachable or longer needles typically use HDSS. To meet this need, detachable 
syringes or needles with reduced dead space (detachable LDSS, see Figure 1) have been developed. 
Studies suggest that detachable syringes with low dead space needles (second syringe in Figure 1) can 
retain less viable HCV and HIV than traditional detachable syringes(8,19), either with rinsing or not 
and before or after storage, although some differences are not statistically significant.  
We introduced an intervention to support the introduction of detachable LDSS (detachable syringes 
with low dead space needles) in Bristol Drugs Project (BDP)(20) in April 2016, nearly replacing all 
detachable HDSS by 2018. Our analysis assesses the cost-effectiveness of this intervention, compared 
to a counterfactual scenario where the intervention was not implemented.  
Methods  
Model description 




The model is open, with individuals entering due to initiation of injection drug use (IDU), and leaving 
due to mortality. Individuals experience a risk of infection due to their IDU, dependent on the 
prevalence of HCV among PWID and the degree to which PWID use different types of needle/syringe. 
If infected, some individuals spontaneously clear their infection and become susceptible to infection 
again, while the remainder develop chronic HCV infection and progress through the disease states in 
Figure 2. Current PWID can cease injecting whereupon they enter the ex-injector state. Susceptible 
individuals in this state can no longer become HCV-infected, but if already infected they continue to 
progress through the same HCV disease states.   
All individuals experience the same background mortality rate, with current PWID also experiencing 
drug-related mortality(22) while those in the decompensated cirrhosis, hepatocellular carcinoma 
(HCC), liver transplant and post-transplant states experience liver-related mortality(23). PWID with 
HCC or undergoing liver transplant are assumed to not be injecting and so are not infectious.  
Individuals in the mild, moderate or compensated cirrhosis states of chronic HCV infection can receive 
HCV treatment. Treatment involves direct-acting antivirals (DAA), which have high cure rates 
(sustained viral reponse [SVR] is 95%) and 12-week duration(24–27). For those who achieve SVR in the 
mild and moderate states, no further disease progression occurs, whereas disease progression rates 
are reduced by 77-78% for those who achieve SVR in the cirrhosis state(28,29); this progression 
continues at the same rate once they reach decompensated cirrhosis or HCC. PWID who achieve SVR 
can be re-infected at the same rate as for their primary infection.  
The model uses a cycle length of 1 year, with half-cycle correction(30). The differential equations for 
the model are in the supplementary materials. 
 
Model parameterisation 
The model was parameterised using data from surveys among PWID in Bristol and the published 
literature (Table 1 and 2). Cost and intervention-related data was provided by BDP.  
Transmission parameters for different syringe types 
The model assumes that fixed LDSS, detachable LDSS and detachable HDSS are associated with 
differing HCV transmission risk. However, given the lack of direct estimates for the effectiveness of 
each type of syringe for reducing the risk of HCV transmission among PWID, indirect estimates of their 
relative infectiveness was obtained from syringe experiments undertaken by Binka et al(8). These 
experiments estimated the degree to which viable hepatitis C virus could be recovered from different 
types of the syringe following contamination with HCV-spiked plasma and their plunger fully 
depressed. Fixed LDSS (insulin syringes) were compared with detachable HDSS (tuberculin syringes) 
and two types of detachable LDSS. Here, we only consider the Nevershare detachable LDSS with low 
dead space needle because this was used in Bristol. In the experiments done by Binka(8), they found 
that fixed LDSS had the fewest syringes with detectable virus, while detachable LDSS had fewer 
syringes with detectable virus than detachable HDSS. The proportion detectable also depended on the 
gauge of the needle used (Table 3). Among syringes with detectable virus, they also found that fixed 
LDSS had the lowest quantity of detectable virus, with detachable LDSS having less than detachable 
HDSS (Table 3). This data was used to produce estimates for the relative infectivity of the different 
syringe types by assuming infectivity was related to the product of the proportion of syringes that 
have detectable virus and the amount of residual detectable virus in those syringes. Our calculations 
 
 
also assumed that 46.1% of detachable needles are 23G1¼" gauge and 53.9% are 25G” gauge, based 
on Bristol data. In the probabilistic sensitivity analysis, we incorporated uncertainty in these estimates 
by sampling (10,000 times) from the uncertainty distributions for the proportion of detachable 
syringes that were each type of gauge (beta distribution), the proportion of each type of syringe that 
had detectable virus (beta distribution), and the quantity of detectable virus found in each type of 
syringe (gamma distribution). These calculations suggest that detachable LDSS are 47.5% (95% 
credibility interval or CrI  33.5-58.9%) less infectious than detachable HDSS and fixed LDSS are 73.5% 
(95%CrI 63.3-81.5%) less infectious, where the 95% credibility intervals are calculated as the central 
95% percentile range across the different sampled estimates. 
Injecting drug use related parameters before and following the intervention 
The annual rate of sharing needles in Bristol is estimated to be 103, based on reported rates of needle 
sharing of 16% from Public Health England(31) and data suggesting PWID in Bristol inject 
approximately 646 times per year(31). Table 1 displays the distribution of syringe types used by PWID 
in Bristol prior to and in the years following the targeted intervention. Just considering the use of 
detachable syringes, this syringe distribution data shows that the intervention resulted in 8%, 58% and 
95% of HDSS being replaced by detachable LDSS in 2016, 2017 and 2018, respectively. Table 2 gives 
the rate of drug-related death in PWID(22) and the duration until cessation of injecting(32).  
Cost and associated inputs 
The perspective adopted in the cost-effectiveness analysis was that of the National Health Service and 
Personal Social Services in Bristol. Considered costs included those associated with buying the 
syringes, implementation of the targeted intervention, HCV treatment and medical resource use.  
BDP estimated that the initial implementation of the targeted intervention required one working day 
for two members of staff to develop and design educational posters for service users (16 hours, 
assuming an 8-hour work day), 45 minutes of initial training for 20 staff members on the benefits of 
detachable LDSS, who to offer them to, and how to encourage their use (15 hours), and 30 minutes of 
refresher training for 20 staff members (10 hours), totalling 41 hours of staff time.  
The costs of printing educational posters was negligible given that fewer than ten posters were printed 
on-site. BDP confirmed that conversations with PWID on the advantages of detachable LDSS (less 
wasted drug and lower risk of transferring infection) would not extend the standard duration of a 
needle exchange conversation. However, a scenario was considered in which all needle exchange 
discussions were extended by 5 minutes.  
The salary range for relevant staff members at BDP was £21,792-26,948, which we averaged to 
£24,370. Assuming standard working hours, this equates to an hourly rate of £13.07. The cost of 
implementing the targeted intervention was therefore £536 (=41 x £13.07), which we conservatively 
assumed to be incurred annually for the duration of the intervention. In the scenario where all  needle 
exchange conversations were extended by 5 minutes, an additional cost of £595 (=546 x 1/12 x £13.07) 
was applied each year based on 546 needle exchange conversations taking place where HDSS were 
requested in the year following the introduction of detachable LDSS. 
All costs were valued in 2017 UK pounds. Where necessary, costs were inflated to 2017 prices using 
the hospital and community health services pay and prices index from Curtis(33). Costs used in the 
model are presented in Table 2. BDP provided the costs of injecting equipment, with fixed LDSS costing 
£0.050, detachable LDSS costing £0.033 and HDSS costing £0.025. On average, 303 syringes were given 
 
 
to each PWID per year. Staff training costs were obtained directly from BDP (Table 2). Based on recent 
data, we assume that 18 (or 2%) chronically infected PWID receive DAA HCV treatment annually in 
Bristol at a cost of £15,000 per treatment, with 95% achieving SVR(34). Other healthcare costs for 
each disease stage come from existing literature. 
Utilities and HCV progression parameters 
Utility values for each health state and the utility decrement for DAA treatment are presented in Table 
2, as are the annual disease progression transition probabilities, using existing literature.   
Model calibration  
In the absence of HCV treatment for PWID, the model was calibrated to give a stable population 
(after 50 years) of 2,770 PWID as estimated for Bristol(35), and a prevalence of chronic HCV infection 
of 42.5%(36). This calibration assumed midpoint estimates for all parameters, except for the annual 
number of individuals initiating injecting drug use and the transmission probability for sharing a 
HDSS, which were varied to calibrate the model, giving calibrated values of 260 and 0.40%, 
respectively. We refer to this calibrated model run as the baseline model fit. For this analysis, the 
baseline model fit was then run with HCV treatment available from 2009, either including the 
detachable LDSS intervention from 2016 (intervention scenario), or a counterfactual scenario where 
no detachable LDSS intervention occurred.  
Cost-effectiveness analysis 
To estimate the impact and cost-effectiveness of the BDP intervention, total costs and QALYs were 
calculated for both the intervention scenario and the counterfactual over a 50-year time horizon: the 
intervention was assumed to run for 10 years with outcomes observed over the subsequent 40 years 
to capture prevention and morbidity benefits. As the intervention scenario was associated with 
reduced costs and increased QALYs, the incremental cost-effectiveness ratio (ICER; a standard 
representation of cost-effectiveness) could not be interpreted and so the net monetary benefit (NMB 
= (incremental QALYs x willingness-to-pay threshold) – incremental costs) was calculated. A 
willingness-to-pay threshold of £20,000 per QALY was assumed, as recommended by NICE(37). Costs 
and outcomes were discounted at a rate of 3.5% per annum.  
Sensitivity analysis 
One-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA) were performed on the 
impact and cost-effectiveness projections where parameters in the baseline model fit were varied. 
The parameter ranges used in OWSA (95% confidence intervals where available; otherwise +/- 25%) 
and probability distributions used in PSA are in Table 2.  
Scenario analyses were also considered in which the time horizon was set to 10 years and 20 years 
instead of 50 years; outcomes discounted at 1.5% instead of 3.5%; the cost of implementing the 
targeted intervention was doubled (£1,072 Instead of £536); an additional 5 minutes was needed per 
needle exchange conversation; treatment costs decrease from £15,000 to £7,500 in Year 4 onwards; 
and the antiviral treatment rate is doubled or tripled from Year 2 onwards. 
Threshold analysis on effectiveness of detachable LDSS 
Given the uncertainty in our estimates of the relative infectivity of the different syringes, a threshold 
analysis was conducted to determine the required reduction in transmission risk for detachable LDSS 
 
 
compared to HDSS that results in the targeted intervention either being cost-saving or cost-effective 
at a threshold of £20,000 per QALY. Results are also presented assuming a wide range of values for 
the reduction in transmission risk due to detachable LDSS compared to HDSS, from 0% to 100% in 10% 
increments. We do not consider the scenario where detachable LDSS may increase transmission risk 
compared to HDSS because it is known that this scenario would not be cost-effective. 
Results  
Cost-effectiveness results 
The targeted intervention was associated with cost savings of £4,116,401 and increases in QALYs of 
1,000 over the 50-year timeframe (Table 4); i.e. the intervention is cheaper and results in better 
health outcomes than the counterfactual of not distributing detachable LDSS. Although the targeted 
intervention is associated with a small increase in equipment and implementation costs, there are 
considerable savings in HCV treatment costs and HCV-related care costs, resulting in substantial 
overall savings (Table 4). Assuming a willingness-to-pay threshold of £20,000 per QALY saved, the 
NMB was calculated to be £24,118,699. The intervention also results in a 30% reduction in incident 
infections over the 10-year intervention (from 1,092 to 765 infections in the PWID population in 
Bristol, or 327 infections averted), which diminishes to a 10% reduction in incident infections over 
the 50-year time horizon (from 5,224 to 4,704, or 520 infections averted).  
Sensitivity analyses 
Univariate sensitivity analysis 
The 10 most influential parameters affecting the NMB of the intervention, when varied individually, 
are presented in Figure 3. The most influential parameter is the long-term uptake of detachable LDSS 
following the intervention. All parameter variations still resulted in the intervention being associated 
with a reduction in costs and an increase in QALYs, and so the results of the base-case analysis are 
considered robust. 
Scenario analyses 
For all considered scenarios, the intervention was cheaper and resulted in better health outcomes 
than not distributing detachable LDSS (Figure 4). Reduced time horizons of 10 or 20 years (instead of 
50 years) were associated with reductions in NMB of 90% and 65% versus the base-case. Conversely, 
lower discounting of outcomes (1.5% instead of 3.5%) resulted in a substantial increase in NMB of 
57%. Doubling the cost of implementing the intervention (£1,072 instead of £536) and assuming an 
additional 5 minutes per needle exchange concversation, resulted in negligible changes (<1%) in the 
NMB. Future decreases in HCV treatment costs (halved in 4 years) were associated with a small (4%) 
decrease in NMB, while doubling or tripling future treatment rates decreased the NMB by 3% and 6%, 
respectively. 
Threshold analysis 
In the base-case analysis, detachable LDSS were associated with a 47% reduction in transmission risk 
compared to HDSS (as calculated in the methods). The threshold analysis demonstrates that 
detachable LDSS only have to be associated with a negligible reduction in transmission risk (0.26%) in 
 
 
order for the intervention to be cost-saving, with this reducing to 0.04% for the intervention to be 
cost-effective at a willingness-to-pay threshold of £20,000 per QALY. Results associated with different 
reductions in transmission risk of between 0% and 100% for detachable LDSS (versus detachable HDSS) 
are presented in Supplementary Table 3, showing that detachable LDSS are cost-saving except for 
when they are not associated with a reduction in transmission risk. 
Probabilistic sensitivity analysis 
The results of 10,000 PSA simulations were plotted on the cost-effectiveness plane (CEP) 
(Supplementary Figure 1) with the point estimates and 95% credility intervals for the QALYs and costs 
being shown in Table 5. All simulations showed the targeted intervention to be associated with overall 
lower costs and more QALYs compared with the counterfactual where the intervention is not 
implemented. The mean incremental costs over the simulated results were -£3,896,754 (95%CrI -
£6,313,555 to -£2,121,271), and the mean incremental QALYs was 951 (95%CrI 455-1,635), which is 
relatively consistent with the base-case change in costs and QALYs of -£4,116,401 and 1,000, 
respectively. The PSA also gave estimates for the relative decrease in new HCV infections over 10 years 
(30%, 95%CrI 18-44%) and 50 years (11%, 95%CrI 4-22%), and the relative decrease in HCV prevalence 




Replacing traditional HDSS with detachable LDSS through NSPs is likely to be a cost-saving strategy for 
reducing the transmission of HCV. These results were robust to all sensitivity analyses. Threshold 
analyses suggested that detachable LDSS would only need to reduce the risk of HCV transmission by 
0.26% compared to HDSS to be cost-saving, and 0.04% to be cost-effective at a willingness-to-pay 
threshold of £20,000 per QALY gained as recommended by NICE.  
 
Strengths and limitations 
This is the first analysis to evaluate the cost-effectiveness of using any type of detachable LDSS 
compared with HDSS. The key limitation of the analysis is the lack of direct evidence for the efficacy 
of detachable LDSS in reducing HCV transmission risk among PWID compared to HDSS. Better data is 
needed on this to determine the impact that using LDSS could have on reducing ongoing HCV and HIV 
epidemics. However, this uncertainty should not stop the expansion of using these syringes because 
our threshold analyses demonstrated that detachable LDSS would only have to result in a very small 
reduction in HCV transmission risk (compared to HDSS) of less than 1% for their use to be cost-saving.  
The analysis solely focussed on Bristol. Although this may suggest the results are not generalisable, 
the incorporation of resource use and cost inputs from an ongoing intervention (by Bristol Drugs 
Project) means it is based on real data, whilst the robustness of the findings to extensive sensitivity 
analyses suggest its relevance to other settings. The evaluation of the targeted intervention in terms 
of prevention of HCV outcomes makes our analyses conservative, given that detachable LDSS may also 
 
 
reduce the transmission of HIV and other blood borne viruses. The estimated reduction in healthcare 
costs and increase in QALYs could therefore be higher.  
Several simplifying assumptions were made in relation to the transmission dynamics of HCV among 
PWID. Importantly, we did not incorporate heterogeneities in risk behaviour among PWID or 
restrictions in who they mix with. This is consistent with other economic evaluations of HCV 
treatment(21,23,38,39). It is known, however, that many PWID share injecting equipment with a 
restricted group of injection partners(40), and so HCV may spread rapidly within such groups without 
necessarily passing from one group to another. Although further analyses should consider how these 
complexities may affect the cost-effectiveness of detachable LDSS, the robustness of our findings 
suggest they are unlikely to change the conclusion that detachable LDSS are a highly cost-saving 
strategy for reducing the transmission of HCV. 
Another uncertainty is in our understanding of how the cost-effectiveness of detachable LDSS may 
change with ongoing increases in HCV treatment uptake or reductions in treatment cost, which are 
occurring in many countries as they attempt to reach the WHO target of eliminating HCV as a public 
health threat by 2030(41). Our analyses suggest the use of detachable LDSS should remain highly cost-
saving despite any changes in the costs and uptake of treatment, again emphasising the robustness of 
our results in the face of considerable unknowns.  
Implications and Conclusions 
Despite uncertainty in the effectiveness of detachable LDSS, the results of our analysis suggest that 
the introduction of detachable LDSS through NSPs in Bristol is likely to be a cost-saving intervention 
that results in improved health outcomes. Because of the robustness of our findings, our results are 
likely to be generalisable to other regions of the UK and elsewhere. In many UK regions, detachable 
LDSS are not currently available, although in Scotland there has been a complete, unphased 
replacement of HDSS in response to an ongoing HIV epidemic(42). Wales has also rolled out 
detachable LDSS. In all settings, it is advised that to enhance the acceptability of detachable LDSS to 
service users, NSPs should transition gradually from distributing traditional HDSS to distributing 
detachable LDSS, while strongly encouraging and promoting their use to service users that currently 
use HDSS without alienating them. This should involve informing PWID of the reasons for their 
introduction(20). Unfortunately, uncertainty in the effectiveness of LDSS still hinders our 
understanding of the impact that this strategy could have if scaled up, and so the importance of 
detachable LDSS for controlling overall levels of HCV is unknown. Although well-designed studies are 
needed to obtain direct evidence of their effectiveness, these data are unlikely to change the 
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Table 1: Distribution of syringe types given out prior to and following the intervention 
Type of syringe used Proportion used 
prior to targeted 
intervention 
(before 2016) 
Proportion used following targeted intervention 
2016  2017 2018 onwards 
Fixed LDSS 62% 62% 62% 62% 
Detachable LDSS 0% 3% 22% 36% 
HDSS (detachable) 38% 35% 16% 2% 
% of detachable 
syringes that are LDSS* 
0% 8% 58% 95% 















n for PSA† 
Reference 
Disease progression parameters 
Spontaneous clearance of HCV 26% 20% - 33% +/-25% Beta (43) 
Excess mortality in PWID vs. ex-PWID 
per year 
0.8% 0.6% - 1.1% +/-25% Gamma (22) 
Treatment rate multiplier for PWID 
vs. ex-PWID 
0.54 0.41 – 0.68 +/-25% Normal (36) 
Annual transition probabilities‡ 
Mild to moderate HCV 2.5% 1.8% - 3.3% 95% CI Beta (21) 
Moderate HCV to cirrhosis 3.7% 2.5% - 5.2% 95% CI Beta (21) 
Cirrhosis to decompensated cirrhosis 3.9% 3.0% - 8.3% 95% CI Beta (21) 
Cirrhosis to HCC 1.4% 0.2% - 3.9% 95% CI Beta (21) 
Decompensated cirrhosis to HCC 1.4% 0.2% - 3.9% 95% CI Beta (21) 
Decompensated cirrhosis to 
transplant 
3% 1.2% - 5.6% 95% CI Beta (21) 
Decompensated cirrhosis to death 13% 11.1% - 15.0% 95% CI Beta (21) 
HCC to transplant 3% 1.2% - 5.6% 95% CI Beta (21) 
HCC to death 43% 37.2% - 48.9% 95% CI Beta (21) 
Transplant to death 21% 12.7% - 30.7% 95% CI Beta (21) 
Post-transplant to death 5.7% 3.7% - 8.2% 95% CI Beta (21) 
Mild HCV, moderate HCV or cirrhosis 
to SVR in ex-PWID* 
2.9% 2.1% - 3.6% +/-25% Beta (44) 
SVR (cirrhosis) to decompensated 
cirrhosis (77% reduction compared  to 
chronic infection transition 
probability) 
0.3% 0.1% - 0.8% 95% CI Beta (29) 
SVR (cirrhosis) to HCC (78% reduction 
compared to chronic infection 
transition probability) 
0.3% 0.2% - 0.5% 95% CI Beta (28) 
Syringe costs and distribution 
Fixed LDSS £0.050 £0.04 - £0.06 +/-25% Gamma BDP 
Detachable LDSS £0.033 £0.02 - £0.04 +/-25% Gamma BDP 
HDSS £0.025 £0.02 - £0.03 +/-25% Gamma BDP 
Annual number of syringes issued per 
PWID 
303 227.25 - 378.75 +/-25% Gamma BDP 
Annual cost of implementing targeted intervention 
Staff time £536 £402 -£670 +/-25% Gamma BDP 
Antiviral treatment costs 
12-week course of sofosbuvir + 
ledipasvir 
£15,000 £11,250 - 
£18,750 
+/-25% Gamma Assumed cheaper 
than list price of 
£38,979.99 (45) 
Annual cost of medical resource use 
Mild HCV £87 £63 - £105 +/-25% Gamma (46) 
Moderate HCV £458 £333 - £555 +/-25% Gamma (46) 
Cirrhosis £714 £519 - £865 +/-25% Gamma (46) 
Decompensated cirrhosis (infected or 
SVR) 
£11,446 £8,323 - 
£13,872 
+/-25% Gamma (46) 
HCC (infected or SVR) £10,198 £7,416 - 
£12,360 
+/-25% Gamma (46) 
Liver transplant (infected or SVR) £46,164 £33,570 - 
£55,949 
+/-25% Gamma (46) 
Post-transplant £2,131 £1,548 - £2,580 +/-25% Gamma (21) 
 
 
Uninfected with SVR (mild HCV) £313 £228 - £380 +/-25% Gamma (23) 
Uninfected with SVR (moderate HCV) £916 £666 - £1,110 +/-25% Gamma (46) 
Uninfected with SVR (cirrhosis) £1,428 £1,038 - £1,731 +/-25% Gamma (46) 
Health state utility values 
Uninfected (PWID) 0.85 0.80 - 0.90 As in (21) Beta (21) 
Uninfected (ex-PWID) 0.90 0.85 - 0.95 As in (21) Beta (47) 
Mild HCV 0.77 0.74 - 0.80 95% CI Beta (46) 
Moderate HCV 0.66 0.60 - 0.72 95% CI Beta (46) 
Cirrhosis 0.55 0.44 - 0.65 95% CI Beta (46) 
Decompensated cirrhosis (infected or 
SVR) 
0.45 0.39 - 0.51 95% CI Beta (46) 
HCC (infected or SVR) 0.45 0.39 - 0.51 95% CI Beta (46) 
Liver transplant (infected or SVR) 0.45 0.39 - 0.51 95% CI Beta (46) 
Post-transplant (infected or SVR) 0.67 0.53 - 0.79 95% CI Beta (46) 
Uninfected with SVR (mild HCV) 0.82 0.62 - 1.03 +/-25% Beta (48) 
Uninfected with SVR (moderate HCV) 0.72 0.54 - 0.90 +/-25% Beta (48) 
Uninfected with SVR (cirrhosis) 0.60 0.45 - 0.75 +/-25% Beta (48) 
Utility decrements 
Antiviral treatment 0.06 0.05 - 0.08 +/-25% Beta (49) 
† All distribution parameters are estimated assuming that the ‘range for sensitivity analysis’ 
represents the 95% confidence interval. 
‡ All transition probabilities converted to instantaneous rates for use in the model. 
* Calculated as the treatment rate (3%) multiplied by the sustained viral response rate (95%). 
Abbreviations: BDP, Bristol Drugs Project; CI, confidence interval; HCC, hepatocellular carcinoma; 
HCV, hepatitis C virus; HDSS, high dead space syringe; LDSS, low dead space syringe; PWID, people 
who inject drugs; SVR, sustained viral response. 
 
Table 3: Relative infectiousness of different syringe types following contamination with HCV virus; 
including data from Binka et al. Plos one 2015 (8) and estimates derived from that study. 






Fixed LDSS (27G½” gauge) 47% (42/90) 4978 ± 3570  2323.1 
Detachable HDSS (23G1¼"  gauge) 95% (57/60) 9861 ± 7026  9368.0 
Detachable HDSS (25G” gauge) 88% (53/60) 9339 ± 6841  8249.5 
Detachable LDSS (23G1¼" gauge) 65% (39/60) 7127 ± 5406  4632.6 
Detachable LDSS (25G” gauge)  80% (48/60) 5724 ± 4014  4579.2 
*The residual infectivity or quantity of detectable virus was estimated using luminescence 
measurements in relative luciferase units (RLUs), as given out by the virus – see Binka et al. (8) for 
more details. The range is the standard deviation around the mean measure as given in Binka et al; 
**Infectivity measure is the product of the percentage of syringes that are detectable and the 




Table 4: Difference in costs (total and disaggregated) and QALYs for the intervention (detachable 






Incremental difference in 
costs and QALYs 
Syringe costs £840,104 £857,136 £17,032 
Implementation costs £0 £4,685 £4,685 
HCV treatment costs £17,189,423 £15,362,552 -£1,826,871 
HCV-related care costs  £26,567,508 £24,256,260 -£2,311,248 
Total costs £44,597,035 £40,480,634 -£4,116,401 
Total QALYs 136,397 137,398 +1,000 
Abbreviations: HCV, hepatitis C virus; QALY, quality-adjusted life-year. 
 
Table 5: Results of probabilistic sensitivity analysis for the costs and impact of the intervention. 









Total costs £44,125,862 
(£31.2 to 61.8M) 
£40,229,109 
(£28.4 to £57.1M) 
-£3,896,754 
(-£6.3 to -£2.1M) 
 
Total QALYs 136,613 
(114,523 to 161,803) 
137,563 
(115,336 to 162,749) 
951 
(455 to 1,635) 
 
Number of new infections 
over 10 years 
1,092 
(637 to 1718) 
772 
(400 to 1306) 
-320 
(-523 to -175) 
30% 
(18% to 44%) 
Number of new infections 
over 50 years 
5,149 
(2,066 to 9,127) 
4,661 
(1,678 to 8,628) 
-488 
(-790 to -265) 
11% 
(4% to 22%) 
Prevalence of infection after 
10 years 
38% 
(26% to 52%) 
30% 
(21% to 43%) 
-8% 
(-12% to -4%) 
21% 
(13% to 30%) 






Figure 1. Illustration of the dead space in different needle and syringe combinations.  
Produced by NIHR CLAHRC West, NIHR HPRU in Evaluation of Interventions at University of Bristol, 
Bristol Drugs Project, Linnell Communications, Exchange Supplies and Public Health England. This work 



























Figure 2: Model schematic† 
 
† Non-liver-related death may occur from all model health states. 
Key to arrows: Orange = Infection; Blue = Successful treatment; Green = Progression; Black = Death. 
Note: progressions states beyond cirrhosis are duplicated for those that are infected and those that have achieved SVR and are uninfected.  
Abbreviations: HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SVR, sustained viral response. 
 
 
Figure 3: Tornado diagram† for univariate sensitivity analysis where each parameter is varied +/-25% 
or across their 95% confidence intervals where available‡ 
 
† The vertical axis is centred on the base-case net monetary benefit; ‡ Estimates of the 95% 
confidence interval were used. 
Abbreviations: HCV, hepatitis C virus; IDU, injecting drug user; HDSS, high dead space syringe; LDSS, 




Figure 4: Tornado diagram for scenario analysis 
 
Abbreviations: LDSS, low dead space syringe. 
